Janux Therapeutics is a technology company.
Janux Therapeutics has raised $186.0M across 2 funding rounds.
Janux Therapeutics has raised $186.0M in total across 2 funding rounds.
Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies, primarily bispecific T cell engagers using its proprietary TRACTr platform, to treat cancer and autoimmune diseases by directing the immune system against tumors while minimizing systemic toxicities.[2][3][5] It serves cancer patients, starting with solid tumors like prostate cancer via its lead candidate JANX001 (PSMA-targeted TRACTr) in Phase 1 trials, and addresses unmet needs in immunotherapy by overcoming limitations of traditional T cell engagers through tumor-activated mechanisms, masks, and albumin binding for safer, more durable responses.[1][3][5] Growth momentum includes its 2021 IPO, first program entering clinic in 2022, a robust pipeline (e.g., EGFR, TROP2 targets), and a Merck collaboration, positioning it as a key player in oncology biotech from its San Diego base with ~71 employees.[2][5][7]
Founded in 2017, Janux emerged from a vision to pioneer next-generation T cell immunotherapies, building on proprietary platforms like TRACTr to improve upon existing TCEs for cancer.[2][5] Key scientific leadership includes Chief Scientific Officer Dr. Tommy Diraimondo, whose PhD expertise drives discovery and pipeline advancement from preclinical to clinical stages.[1] The company achieved early traction with its June 2021 IPO and dosed the first patient in its lead prostate cancer trial (JANX001) in late 2022, alongside IND plans for additional programs and a strategic research deal with Merck on two targets.[2][5] This data-driven, collaborative culture has fueled rapid progress in San Diego's biotech hub.[2][7][8]
Janux stands out in immunotherapy through these key strengths:
Janux rides the cancer immunotherapy wave, particularly T cell engagers, amid surging demand for precise, tolerable treatments in a $100B+ oncology market driven by aging populations and immunotherapy breakthroughs like checkpoint inhibitors.[1][2][5] Timing aligns with post-2020 advances in bispecifics (e.g., approved TCEs), where Janux's masked, tumor-conditional tech addresses key pain points like toxicity, enabling broader solid tumor applications beyond liquid cancers.[3][5] Favorable forces include biotech funding recovery, regulatory nods for novel modalities, and partnerships like Merck's, amplifying its influence; it contributes to San Diego's ecosystem by innovating safer TCEs, potentially reshaping standards for immuno-oncology and autoimmune therapies.[2][7][8]
Janux is poised for pipeline catalysts, with Phase 1 data readouts for JANX001 expected soon, potential INDs/expansions for EGFR/TROP2, and Merck milestones driving value in 2026+.[1][3][5] Trends like AI-accelerated discovery, combo therapies, and autoimmune extensions will shape its path, evolving it from clinical-stage innovator to potential multi-product leader if safety/durability holds. As immunotherapy matures, Janux's platforms could transform cancer care, delivering the durable responses that redefine patient lives—echoing its mission to guide immune systems against disease without compromise.[2][4]
Janux Therapeutics has raised $186.0M in total across 2 funding rounds.
Janux Therapeutics's investors include Avalon Ventures, Domain Associates, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, RA Capital, RiverVest, Jonathan Root, Heather Preston.
Janux Therapeutics has raised $186.0M across 2 funding rounds. Most recently, it raised $130.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $130.0M Series B | Avalon Ventures, Domain Associates, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, RA Capital, RiverVest, Jonathan Root, Heather Preston | |
| Mar 1, 2021 | $56.0M Series A | Avalon Ventures, Domain Associates, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, RA Capital, RiverVest, Jonathan Root, Heather Preston |